Current Report Filing (8-k)
September 24 2020 - 04:20PM
Edgar (US Regulatory)
0001041024FALSE00010410242020-09-242020-09-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 24, 2020
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
Delaware |
000-23661 |
38-3317208 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
411 Hackensack Avenue, Suite 501, Hackensack, New Jersey
07601
(Address of principal executive offices, including zip
code)
(248) 960-9009
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
|
|
|
|
|
|
|
|
|
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
|
|
|
|
|
|
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
|
|
|
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
|
|
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c) |
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of Each Class |
|
Trading Symbol |
|
Name of Each exchange on which
registered |
Common Stock, par value $0.0001 |
|
RMTI |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the
Exchange Act.
☐
|
|
|
|
|
|
|
|
|
Item 7.01 |
|
Regulation FD Disclosure. |
On September 24, 2020, Rockwell Medical,
Inc. made available an updated investor presentation regarding new
indications opportunities for Ferric Pyrophosphate Citrate. A copy
of the investor presentation is furnished herewith as Exhibit 99.1
and incorporated by reference herein.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and
shall not be incorporated by reference into any registration
statement or other document filed under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
|
|
|
|
|
|
|
|
|
Item 9.01 |
|
Financial Statements and Exhibits. |
(d) Exhibits The
following exhibit is being furnished herewith:
EXHIBIT INDEX
|
|
|
|
|
|
|
|
|
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File, formatted in INline XBRL and
included as Exhibit 101. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
ROCKWELL MEDICAL, INC. |
|
|
|
|
Date: September 24, 2020 |
By: |
/s/ Russell Ellison |
|
|
Russell Ellison |
|
|
Chief Executive Officer |
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Dec 2020 to Jan 2021
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Jan 2020 to Jan 2021